Validation of International Warfarin Pharmacogenetics Consortium (IWPC) Algorithm in Elderly Patients With Comorbidity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

376 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-03-31

Study Completion Date

2018-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to validate the International Warfarin Pharmacogenetics Consortium (IWPC) algorithm in a prospective cohort of elderly people (65 years or older) with heart valves and/or nonvalvular atrial fibrillation (AF) and at least one comorbid condition, and to assess the algorithm's prognostic relevance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacogenetic Dosage Algorithm for Acenocoumarol

NCT03015025

Atrial Fibrillation Venous Thromboses Cardiac Valve Disease

COMPLETED

Early Identification of Warfarin Maintenance Dosage

NCT01178034

Atrial Fibrillation

COMPLETED PHASE3

Following Patients on Warfarin Therapy to See if Differences in Hemorrhagic Complications Exist

NCT00075985

Atrial Fibrillation

COMPLETED

Anticoagulation Regiments in Patients With Prosthetic Heart Valve Thrombosis

NCT02240953

Thrombosis

UNKNOWN NA

Genotype-guided Warfarin Individualized Treatment

NCT02211326

Atrial Fibrillation Deep Venous Thrombosis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Thrombus Due to Heart Valve Prosthesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Warfarin in elderly with comorbidity

Patients 65 years or older, candidate for therapy with warfarin for non valvular atrial fibrillation or heart valve replacement

Warfarin

Intervention Type DRUG

warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Warfarin

warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 65 years
* Patients who initiate warfarin because of non valvular atrial fibrillation or heart valve replacement
* At least one comorbid condition
* At least two other drugs regularly assumed over and above warfarin